2023年4月30日

Relievant Medsystems——一個公司致力於把vertebrogenic疼痛的診斷和治療,一種慢性下腰痛(CLBP)宣布,它已經完成了關閉的G係列融資5000萬美元。資金是由新投資者盟友橋組與現有投資者參與“奮進號”願景,Vensana首都Lightstone企業,新企業Associates迦南合作夥伴和morgenthal的企業。在美國有3000萬人患有慢性下腰痛和1 6可能vertebrogenic疼痛,這是一個不同類型的慢性下腰痛引起的椎體終板損傷、椎間盤和椎體之間的接口。中間的病人通常有疼痛的腰,彎腰時加重,長時間坐著,或者當他們是活躍的。醫生能夠確認病人的痛苦是通過觀察Modic vertebrogenic變化,生物標誌物在標準核磁共振表明炎症在椎體終板。Relievant Medsystems“微創Intracept過程被稱為唯一fda治療慢性vertebrogenic下腰痛,使用有針對性的射頻能量阻止basivertebral神經(BVN)傳遞疼痛信號到大腦。和執行的過程通常是在一個門診手術中心,大約需要1小時。和現有數據的基礎上,患者通常經驗最少需要術後疼痛和一般快速的恢複時間。患者經常感到疼痛治療的2周內Intracept過程。關鍵引用:“這大量額外的資金可以讓我們進一步加速努力改變vertebrogenic疼痛的診斷和治療。 We are thrilled to see strong support from Ally Bridge Group and existing investors in this oversubscribed round as we expand Intracept adoption and make this treatment available to more patients and physicians.” — Tyler Binney, President and CEO of Relievant Medsystems “We are pleased to join the investor syndicate supporting Relievant. We have been impressed by the company’s novel and clinically proven technology and accelerating commercial traction and adoption. We are excited to partner with the company on its journey to provide relief for the millions of patients in the U.S. suffering from chronic low back pain indicated for Relievant’s Intracept Procedure.” — Kevin Reilly, a Managing Director at Ally Bridge Group Trending on Pulse 2.0